Enterprise Value

1.529B

Cash

520.5M

Avg Qtr Burn

-24.61M

Short % of Float

24.56%

Insider Ownership

1.27%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
KT-474 (IRAK4 degrader) Details
Hidradenitis suppurativa, Atopic dermatitis, Rheumatoid arthritis

Phase 2

Data readout

KT-253 Details
Solid tumor/s, Cancer, Acute myeloid leukemia, Lymphoma

Phase 1

Data readout

KT-333 Details
Cancer, Solid tumor/s

Phase 1

Data readout

KT-294 (TYK2 Degrader) Details
Inflammatory disease, Autoimmune disease

Phase 1

Initiation

KT-621 (STAT6 Degrader) Details
Inflammatory disease, Allergy

Phase 1

Initiation

KT-413 Details
Solid tumor/s, Cancer

Failed

Discontinued